Collplant Biotechnologies vs Humacyte
Collplant Biotechnologies is the larger business, with $2.4m of revenue in fiscal 2025 against $2.0m for Humacyte (1.2 times as much). Collplant Biotechnologies kept more of each dollar of sales as profit: a net margin of -484.6% against -2003.6%. Collplant Biotechnologies carries less debt relative to equity (0.0% against 1140.0%).
| Latest fiscal year | Collplant BiotechnologiesCLGN, 2025 | HumacyteHUMA, 2025 |
|---|---|---|
| Revenue | $2.4m | $2.0m |
| Revenue growth | 360.4% | — |
| Net income | −$11.5m | −$40.8m |
| Operating margin | -484.3% | -5306.0% |
| Net margin | -484.6% | -2003.6% |
| Return on equity | -117.6% | — |
| Free cash flow | −$9.4m | −$106m |
| Cash | $5.6m | $50.5m |
| Total debt | $0 | $35.4m |
| Debt to equity | 0.0% | 1140.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 184 |
| Market value | $52.2m | $111m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 5 buys, 2 sales |